摘要
目的:观察口服肝喜片配合三氧化二砷行肝动脉灌注化疗栓塞术(TACE)治疗肝郁脾虚型原发性肝癌患者的近期临床疗效以及不良反应。方法:治疗组(30例):口服肝喜片配合三氧化二砷行TACE;对照组(30例):三氧化二砷行TACE,4周为1个周期,共治疗2个周期。比较两组的中医临床症状、瘤体大小变化、生活质量、不良反应及安全性指标的变化。结果:在中医临床症状方面:治疗后再次对中医临床症状进行打分,经检验两组组间内差异有统计学意义(P<0.05,P<0.01),提示治疗组中医临床症状改善情况优于对照组;瘤体大小变化:两组治疗后瘤体大小较前均有所缓解,治疗后对两组瘤体有效率及稳定率进行统计学分析,经检验,组间差异无统计学意义;在生活质量方面:通过比较两组治疗前后Karnofsky评分,组间差异有统计学意义(P<0.05),提示治疗组改善生活质量情况优于对照组;两组发生不良反应情况进行比较,两组治疗后均有部分患者出现不同程度的不良反应,治疗组发生不良反应例数明显低于对照组(P<0.01)。治疗组与对照组生存期比较,治疗组在延长无进展生存期(PFS)、总生存期(OS)上有明显优势。结论:口服肝喜片配合三氧化二砷行TACE治疗肝郁脾虚型原发性肝癌临床疗效确切,可更有效地改善患者生活质量和临床症状,减轻三氧化二砷不良反应,安全方便,值得临床推广。
Objective： To explore the short-term clinical effect and toxicity reaction of treating primary hepatic carcinoma patients with syndrome of stagnation of liver qi and spleen deficiency with oral Ganxi Tablets combined with arsenic trioxide by transcatheter arterial chemoembolization（TACE）. Methods： Thirty patients in treatment group were treated with combination of oral Ganxi Tablets and arsenic trioxide via TACE, and 30 patients in control group were treated with arsenic trioxide via TACE for 8 weeks. The TCM symptoms, timorous size, life quality, adverse reaction and safety indexes of patients in the two groups were compared. Results： Scored the TCM symptoms of patients in the two groups after treating, the difference was statistically significant between the two groups（P0.05, P0.01）, which suggested that improvement in TCM symptoms of patients in treatment group was superior to that of control group. The tumor sizes of patiens in the two groups were all relieved after treating, and the efficiency and stability of tumor of patients in the two groups were statistically analyzed after treatment, and the test results showed that there was no statistically significant difference between the two groups. The Karnofsky score of life quality of patients in the two groups were scored before and after treatment, and the results showed that there was statistically significant difference between the two groups（P0.05）, which reflected that the life quality of patients in treatment group was significantly better than that of control group. The adverse reactions were appeared in patients of the two groups at different levels, but the adverse reactions of treatment group accounted for less than the control group, and the difference between the two groups was significant（P0.01）. Compared with control group, treatment group had obvious advantages in prolonging PFS and OS of patients. Conclusion： The oral Ganxi Tablets combined with arsenic trioxide by TACE is applied in treating hepatic carcinoma patients with syndrome of stagnation of liver qi and spleen deficiency with obvious clinical curative effect, which could improve the life quality and TCM symptoms of patients, and reduce the adverse reactions of arsenic trioxide. It is security and convenient and worth to be popularized in clinic.
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2016年第3期1121-1125,共5页
China Journal of Traditional Chinese Medicine and Pharmacy
关键词
三氧化二砷
肝喜片
原发性肝癌
临床研究
肝郁脾虚
肝动脉灌注化疗栓塞术
Arsenic trioxide
Ganxi Tablets
Primary hepatic carcinoma
Clinical research
Stagnation of liver qi and spleen deficiency
Transcatheter arterial chemoembolization
